Lilly completes Adverum acquisition for $3.56 per share plus CVRs

Go back to Lilly completes Adverum acquisition for $3.56 per share plus CVRs

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

December 9, 2025 8:29 AM UTC

INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)  and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued... More